We initiate coverage on Vylor with a Sell rating and a $65.00 price target. At 18.6 times 2027 operating EBITDA and 29 times earnings, the stock misprices litigation risks and frozen capital returns.
Key points
- 18.6 times projected 2027 enterprise value to operating cash flow overvalues Vylor relative to historical peers.
- $5.6 billion in post-separation debt and frozen shareholder payouts create unexpected capital structure overhang following October litigation.
- $65.00 price target implies 15.5% downside as pure-play enthusiasm cools and legal restrictions defer dividends.
The call
The market prices in perfection by valuing Vylor at 18.6 times 2027 operating cash flow and 29 times earnings. That premium requires uninterrupted 8% profit compounding, pristine commercial execution across Brazilian corn and North American soybeans, and frictionless separation from legacy chemical liabilities.
Quarterly seed operating EBITDA trend and 2026 bridge- Reported seed EBITDA
- Forecast seed EBITDA
Historical predecessor seed segment EBITDA and Vylor management targets ($ millions)
We believe the market is too optimistic about standalone valuation and capital returns. Legal challenges by 15 states prompted an injunction stay conditioned on freezing dividends and buybacks. Without capital returns and carrying $4.5 billion of net debt, the multiple should compress to 15.5 times 2027 operating profit before depreciation and amortization.
Implied share price sensitivity to 2027 EV/EBITDA multipleEstimated 12-month equity value per share under varying 2027 EV/EBITDA multiples
Valuation
We value Vylor using an enterprise value to earnings before interest, taxes, depreciation, and amortization framework based on management's 2027 target trajectory.
| Valuation metric | 2027 estimate |
|---|
| Projected operating EBITDA | $3,010 million |
| Target EV/EBITDA multiple | 15.5 times |
| Projected enterprise value | $46,655 million |
| Less: projected net debt | $3,200 million |
| Projected equity value | $43,455 million |
| Diluted shares outstanding | 667.3 million |
| 12-month price target | $65.00 per share |
A 15.5 times multiple reflects premier germplasm assets offset by $5.6 billion in gross debt and frozen capital distributions. At 29.0 times 2027 earnings per share, current prices offer negative asymmetry against cyclical farm income headwinds.
Risks
- Court lifting of distribution restrictions sooner than expected, which would allow initiation of the planned dividend.
- Sharp recovery in crop commodity prices, expanding farmer margins and driving higher premium seed adoption.
- Accelerated trait licensing revenue outperforming management's net royalty neutrality milestones.
What would change my mind
A swift legal resolution that confirms zero legacy liability exposure and permits immediate initiation of shareholder dividends would change my mind.